 |
(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N’-bis(2-bromoethyl) diamidophosphate |
|---|---|
| Trade Name | |
| Orphan Indication | Soft tissue sarcoma |
| USA Market Approval | USA |
| USA Designation Date | 2012-03-09 00:00:00 |
| Sponsor | Threshold Pharmaceuticals, Inc.;170 Harbor Way, Suite 300;South San Francisco, California, 94080 |
